PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Royal DSM N.V.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DSM Completes Acquisition of Stake in Andre Pectin (China) - Royal DSM, the global Life Sciences and Materials Sciences company, announced that it has completed the acquisition of a 19% equity interest in Yantai Andre Pectin Co. Ltd (Andre Pectin), a China based producer of texturing ingredients - DSM.com
DSM Completes Acquisition of Stake in Andre Pectin (China)

 

NewswireToday - /newswire/ - Heerlen, Netherlands, 2013/10/09 - Royal DSM, the global Life Sciences and Materials Sciences company, announced that it has completed the acquisition of a 19% equity interest in Yantai Andre Pectin Co. Ltd (Andre Pectin), a China based producer of texturing ingredients - DSM.com. Euronext: DSM KON

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DSM announced this acquisition on 5 May 2013.

DSM (dsm.com) had previously acquired a 10% stake in Andre Pectin from Hony Capital. DSM’s total interest in Andre Pectin is now 29%. The parties have agreed that DSM has option rights to increase its stake in Andre Pectin to a majority stake at a later stage.

Andre Pectin, headquartered in Yantai (Shandong Province, China), was established in 2003 and is active in the manufacturing and sale of apple and citrus pectin, a key food hydrocolloid providing texture, as well as pectin related food products. Andre Pectin realizes annual net sales of around €30 million. As the only successful global pectin market entrant in the past 20 years, Andre Pectin is the only significant pectin manufacturer in Asia with premier access to the world’s fastest growing specialty food ingredients market.

With a market size of around €6 billion with an annual average growth rate of 3-5%, the global hydrocolloids market provides an attractive growth area to leverage DSM’s bio-ingredients capabilities and global customer access. Some food hydrocolloids, such as pectin and gellan gum possess unique properties that are highly relevant to a broad range of processed and healthy food applications.

DSM’s investment in Andre Pectin, synergistically combined with the previously acquired gellan gum assets based in China, creates a China-based hydrocolloids growth platform, in line with DSM’s strategy for the Nutrition cluster, Continued Value Growth.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Royal DSM N.V.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DSM Completes Acquisition of Stake in Andre Pectin (China)

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Royal DSM N.V. |
Publisher Contact: Herman Betten - DSM.com 
+31(0)45 5782017 media.relations[.]dsm.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Royal DSM N.V. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Royal DSM N.V. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)